Overall Level of Evidence for Hydrazine Sulfate
Several clinical case series conducted by Russian investigators have indicated that hydrazine sulfate has marginal anticancer activity, but these results are considered inconclusive due to the lack of control groups and insufficient information provided about study methodology. Well-controlled clinical studies conducted in the United States have shown no evidence of anticancer activity. In addition, evidence concerning the effectiveness of hydrazine sulfate as a treatment
for cancer-related cachexia and anorexia is inconclusive. Furthermore,
hydrazine sulfate has been shown to increase the incidence of several types of
tumors in animals, and it has been classified as a potential carcinogen by the
National Toxicology Program of the U.S. Department of Health and Human
Services. The use of hydrazine sulfate as an anticancer drug outside the context of clinical trials
has not been approved by the U.S. Food and Drug Administration and, thus, cannot be recommended.
Separate levels of evidence scores are assigned to qualifying human studies on the basis of statistical strength of the study design and scientific strength of the treatment outcomes (i.e., endpoints) measured. The resulting two scores are then combined to produce an overall score. For additional information about levels of evidence analysis, refer to Levels of Evidence for Human Studies of Cancer Complementary and Alternative Medicine.
Back to Top
< Previous Section | Next Section > |